Surrey Heartlands

Joint Formulary & PAD

Donepezil hydrochloride - Multiple sclerosis

You are here : Home > Formulary Search > Donepezil hydrochloride - Multiple sclerosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

Guidelines (Local)
Dementia Treatment Pathway - Feb 2019
Policy Statement
Acetylcholinesterase inhibitors and memantine for cognitive impairment in Multiple Sclerosis - Policy statement APC 395- 2019 - Mar 19

PAD Profile

ChemicalSubstance :
Donepezil hydrochloride
Indication :
Multiple sclerosis
Group Name :
Keywords :
cognitive impairment in MS
Brand Names Include :
Aricept, Aricept Evess
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Donepezil hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Multiple sclerosis.

Committee Recommendations (2)

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend AChE inhibitors* or memantine for people with cognitive impairment caused by multiple sclerosis, in line with NICE guideline (NG97)

* AChE inhibitors - donepezil, galantamine amd rivastigmine